Anavex Life Sciences Corp (AVXL)

[imho]

Regardless, it looks like we won't have more details for a while. CTAD (though mostly AD, other dementias also presented) is in 2 weeks but its probably too late for a late breaking session. Any peer reviewed article is many months away.

You left out the third catalyst.

ANAVEX®2-73-PDD-001 study results will be submitted for presentation at a medical conference and for publication in a peer-reviewed medical journal. Anavex is planning a pivotal trial of ANAVEX®2-73 (blarcamesine) in Parkinson’s disease dementia after submitting the results of the study to the FDA to obtain regulatory guidance.

It will be interesting to see what the FDA "guidance" will be. If it is positive (whatever that means), it will have more affect on the stock price than the other two.

IMHO